Brian Rini, MD
Hematology & Oncology · Nashville, TNNPI 1144261231
Payments from drug & device makers
Across 572 payments — averaging $14,134 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$3.2M
- Pfizer$2.3M
- AstraZeneca$918K
- Daiichi Sankyo Inc.$400K
- Genentech, Inc.$374K
- E.r. Squibb & Sons, L.L.C.$197K
- plus $622K from 31 others
Across 9 payments — averaging $1134.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$5K
- Pfizer$5K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 218 | $3,237,821 |
| Pfizer(2 entities) | 59 | $2,335,648 |
| AstraZeneca | 16 | $918,397 |
| Daiichi Sankyo Inc. | 32 | $400,211 |
| Genentech, Inc. | 77 | $374,378 |
| E.r. Squibb & Sons, L.L.C. | 32 | $196,732 |
| Novartis | 7 | $195,826 |
| Roche Products Limited | 7 | $130,182 |
| Gilead | 9 | $66,627 |
| Eisai Inc. | 29 | $59,822 |
| GSK | 3 | $25,075 |
| Coherus Oncology, Inc. | 14 | $17,472 |
| USWM, LLC | 2 | $15,000 |
| Eisai CO., LTD. | 3 | $14,275 |
| Astrazeneca UK Limited | 9 | $13,214 |
| EUSA Pharma (US) LLC | 3 | $11,850 |
| Alkermes, Inc. | 3 | $10,700 |
| Hoffmann-la Roche Limited | 2 | $8,396 |
| Eli Lilly | 1 | $8,313 |
| Janssen Research & Development, LLC | 1 | $6,750 |
| Incyte Corporation | 1 | $6,700 |
| F. Hoffmann-la Roche AG | 7 | $6,211 |
| AVEO Pharmaceuticals, Inc. | 13 | $5,554 |
| Whitehall International Inc | 3 | $4,929 |
| Shionogi Inc | 1 | $4,000 |
| Genmab U.S., Inc. | 2 | $3,593 |
| Dr.reddy's Laboratories,inc. | 2 | $3,500 |
| Johnson & Johnson | 1 | $1,388 |
| Tempus AI, Inc | 3 | $1,007 |
| Janssen Scientific Affairs, LLC | 2 | $291 |
| Regeneron Healthcare Solutions, Inc. | 2 | $278 |
| Exelixis Inc. | 1 | $172 |
| Bristol Myers Squibb | 1 | $170 |
| Photocure Inc | 1 | $163 |
| Bayer | 1 | $123 |
| Telix Pharmaceuticals | 3 | $91 |
| Myovant Sciences Inc. | 1 | $18 |
How this compares
$8,084,876 in reported general payments places this provider in the 95th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Nashville
- Erika HamiltonNashville$45.4M
- Ian FlinnNashville$41.2M
- Johanna BendellNashville$28.5M
- Jesus BerdejaNashville$22.2M
- Meredith McKeanNashville$16M
- Krish PatelNashville$14.2M
- Denise YardleyNashville$13.2M
- Todd BauerNashville$10.9M
- Wade IamsNashville$8.9M
- Benjamin GarmezyNashville$8.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.